Cargando…
Carcinogenesis and management of human papillomavirus-associated cervical cancer
Approximately 95% of cervical cancer are caused by human papillomavirus (HPV) infection. Although it is estimated that HPV-associated cervical cancer will decrease with the widespread use of HPV vaccine, it may take time for HPV-associated cervical cancer to be eliminated. For the appropriate manage...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Nature Singapore
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390372/ https://www.ncbi.nlm.nih.gov/pubmed/37294390 http://dx.doi.org/10.1007/s10147-023-02337-7 |
_version_ | 1785082465386233856 |
---|---|
author | Kusakabe, Misako Taguchi, Ayumi Sone, Kenbun Mori, Mayuyo Osuga, Yutaka |
author_facet | Kusakabe, Misako Taguchi, Ayumi Sone, Kenbun Mori, Mayuyo Osuga, Yutaka |
author_sort | Kusakabe, Misako |
collection | PubMed |
description | Approximately 95% of cervical cancer are caused by human papillomavirus (HPV) infection. Although it is estimated that HPV-associated cervical cancer will decrease with the widespread use of HPV vaccine, it may take time for HPV-associated cervical cancer to be eliminated. For the appropriate management of HPV-associated cervical cancer, it is important to understand the detailed mechanisms of cervical cancer development. First, the cellular origin of most cervical cancers is thought to be cells in the squamocolumnar junction (SCJ) of the uterine cervix. Therefore, it is important to understand the characteristics of SCJ for cervical cancer screening and treatment. Second, cervical cancer is caused by high risk HPV (HR-HPV) infection, however, the manner of progression to cervical cancer differs depending on the type of HR-HPV: HPV16 is characterized by a stepwise carcinogenesis, HPV18 is difficult to detect in precancerous lesions, and HPV52, 58 tends to remain in the state of cervical intraepithelial neoplasia (CIN). Third, in addition to the type of HPV, the involvement of the human immune response is also important in the progression and regression of cervical cancer. In this review, we demonstrate the carcinogenesis mechanism of HPV-associated cervical cancer, management of CIN, and the current treatment of CIN and cervical cancer. |
format | Online Article Text |
id | pubmed-10390372 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Nature Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-103903722023-08-02 Carcinogenesis and management of human papillomavirus-associated cervical cancer Kusakabe, Misako Taguchi, Ayumi Sone, Kenbun Mori, Mayuyo Osuga, Yutaka Int J Clin Oncol Invited Review Article Approximately 95% of cervical cancer are caused by human papillomavirus (HPV) infection. Although it is estimated that HPV-associated cervical cancer will decrease with the widespread use of HPV vaccine, it may take time for HPV-associated cervical cancer to be eliminated. For the appropriate management of HPV-associated cervical cancer, it is important to understand the detailed mechanisms of cervical cancer development. First, the cellular origin of most cervical cancers is thought to be cells in the squamocolumnar junction (SCJ) of the uterine cervix. Therefore, it is important to understand the characteristics of SCJ for cervical cancer screening and treatment. Second, cervical cancer is caused by high risk HPV (HR-HPV) infection, however, the manner of progression to cervical cancer differs depending on the type of HR-HPV: HPV16 is characterized by a stepwise carcinogenesis, HPV18 is difficult to detect in precancerous lesions, and HPV52, 58 tends to remain in the state of cervical intraepithelial neoplasia (CIN). Third, in addition to the type of HPV, the involvement of the human immune response is also important in the progression and regression of cervical cancer. In this review, we demonstrate the carcinogenesis mechanism of HPV-associated cervical cancer, management of CIN, and the current treatment of CIN and cervical cancer. Springer Nature Singapore 2023-06-09 2023 /pmc/articles/PMC10390372/ /pubmed/37294390 http://dx.doi.org/10.1007/s10147-023-02337-7 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Invited Review Article Kusakabe, Misako Taguchi, Ayumi Sone, Kenbun Mori, Mayuyo Osuga, Yutaka Carcinogenesis and management of human papillomavirus-associated cervical cancer |
title | Carcinogenesis and management of human papillomavirus-associated cervical cancer |
title_full | Carcinogenesis and management of human papillomavirus-associated cervical cancer |
title_fullStr | Carcinogenesis and management of human papillomavirus-associated cervical cancer |
title_full_unstemmed | Carcinogenesis and management of human papillomavirus-associated cervical cancer |
title_short | Carcinogenesis and management of human papillomavirus-associated cervical cancer |
title_sort | carcinogenesis and management of human papillomavirus-associated cervical cancer |
topic | Invited Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10390372/ https://www.ncbi.nlm.nih.gov/pubmed/37294390 http://dx.doi.org/10.1007/s10147-023-02337-7 |
work_keys_str_mv | AT kusakabemisako carcinogenesisandmanagementofhumanpapillomavirusassociatedcervicalcancer AT taguchiayumi carcinogenesisandmanagementofhumanpapillomavirusassociatedcervicalcancer AT sonekenbun carcinogenesisandmanagementofhumanpapillomavirusassociatedcervicalcancer AT morimayuyo carcinogenesisandmanagementofhumanpapillomavirusassociatedcervicalcancer AT osugayutaka carcinogenesisandmanagementofhumanpapillomavirusassociatedcervicalcancer |